Literature DB >> 18590347

Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.

Parris M Kidd1.   

Abstract

Alzheimer's disease, AD, is the most common form of dementia. AD initially targets memory and progressively destroys the mind. The brain atrophies as the neocortex suffers neuronal, synaptic, and dendritic losses, and the hallmark amyloid plaques and neurofibrillary tangles proliferate. Pharmacological management, at best, is palliative and transiently effective, with marked adverse effects. Certain nutrients intrinsic to human biochemistry (orthomolecules) match or exceed pharmacological drug benefits in double-blind, randomized, controlled trials, with superior safety. Early intervention is feasible because its heritability is typically minimal and pathological deterioration is detectable years prior to diagnosis. The syndrome amnestic mild cognitive impairment exhibits AD pathology and to date has frustrated attempts at intervention. The condition age-associated memory impairment is a nonpathological extreme of normal brain aging, but with less severe cognitive impairment than amnestic mild cognitive impairment. Age-associated memory impairment is a feasible target for early intervention against AD, beginning with the modifiable AD risk factors - smoking, hypertension, homocysteine, type 2 diabetes, insulin resistance, and obesity. Stress reduction, avoidance of toxins, and mental and physical exercise are important aspects of prevention. The diet should emphasize omega-3 fatty acids docosahexaenoic acid and eicosapentaenoic acid; flavonoids and other antioxidant nutrients; and B vitamins, especially folate, B6 and B12. Dietary supplementation is best focused on those proven from randomized, controlled trials: the phospholipids phosphatidylserine and glycerophosphocholine, the energy nutrient acetyl-L-carnitine, vitamins C and E, and other antioxidants. A comprehensive integrative strategy initiated early in cognitive decline is the most pragmatic approach to controlling progression to Alzheimer's disease.

Entities:  

Mesh:

Year:  2008        PMID: 18590347

Source DB:  PubMed          Journal:  Altern Med Rev        ISSN: 1089-5159


  42 in total

1.  The involvement of homocysteine in stress-induced Aβ precursor protein misprocessing and related cognitive decline in rats.

Authors:  Fang Xie; Yun Zhao; Jing Ma; Jing-Bo Gong; Shi-Da Wang; Liang Zhang; Xiu-Jie Gao; Ling-Jia Qian
Journal:  Cell Stress Chaperones       Date:  2016-07-19       Impact factor: 3.667

Review 2.  Vascular basis for brain degeneration: faltering controls and risk factors for dementia.

Authors:  Raj N Kalaria
Journal:  Nutr Rev       Date:  2010-12       Impact factor: 7.110

Review 3.  Brain oxidative stress as basic target of antioxidant traditional oriental medicines.

Authors:  Tetsuya Konishi
Journal:  Neurochem Res       Date:  2008-11-06       Impact factor: 3.996

4.  Alzheimer's disease: a healthcare burden of epidemic proportion.

Authors:  T S Dharmarajan; Srinivas G Gunturu
Journal:  Am Health Drug Benefits       Date:  2009-01

Review 5.  Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 6.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

7.  Anxiety and verbal memory performance in APOE-4 carriers and noncarriers aged 50 years and above.

Authors:  Ashley R Curiel; Karen J Miller; Karen Pollard; Jeanne Kim; Jena Kravitz; Gary W Small
Journal:  Aging health       Date:  2012-02-01

8.  Long-Term Dietary Alpha-Linolenic Acid Supplement Alleviates Cognitive Impairment Correlate with Activating Hippocampal CREB Signaling in Natural Aging Rats.

Authors:  Hui Gao; Peipei Yan; Shun Zhang; Hao Huang; Fenghong Huang; Taoping Sun; Qianchun Deng; Qingde Huang; Sijing Chen; Keqiang Ye; Jiqu Xu; Liegang Liu
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

9.  Spatial reference memory in normal aging Fischer 344 × Brown Norway F1 hybrid rats.

Authors:  Joseph A McQuail; Michelle M Nicolle
Journal:  Neurobiol Aging       Date:  2014-07-03       Impact factor: 4.673

10.  Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease.

Authors:  Alfred N Fonteh; Jiarong Chiang; Matthew Cipolla; Jack Hale; Fatimatou Diallo; Alejandra Chirino; Xianghong Arakaki; Michael G Harrington
Journal:  J Lipid Res       Date:  2013-07-18       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.